Nevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients

Nucleoside reverse transcriptase inhibitor (NRTI) and protease inhibitor (PI)/ritonavir sparing regimens may be useful to some HIV-infected patients. Nevirapine (NVP) and raltegravir (RAL) are both potent antiretrovirals with good long-term safety profiles. We retrospectively identified from our ele...

Full description

Saved in:
Bibliographic Details
Published in:Antiviral therapy 2013-11, Vol.19 (1), p.117-23
Main Authors: Reliquet, Véronique, Chirouze, Catherine, Allavena, Clotilde, Muret, Patrice, Peytavin, Gilles, André-Garnier, Elisabeth, Bettinger, Dominique, Ferré, Virginie, Hoen, Bruno, Raffi, François
Format: Article
Language:English
Subjects:
Antiretroviral Therapy, Highly Active
CD4 Lymphocyte Count
Drug Combinations
Drug Substitution
Female
Follow-Up Studies
HIV Infections
HIV-1
Humans
Life Sciences
Male
Microbiology and Parasitology
Middle Aged
Nevirapine
Protease Inhibitors
Pyrrolidinones
Retrospective Studies
Reverse Transcriptase Inhibitors
Risk Factors
Treatment Outcome
Viral Load
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 23
container_issue 1
container_start_page 117
container_title Antiviral therapy
container_volume 19
creator Reliquet, Véronique
Chirouze, Catherine
Allavena, Clotilde
Muret, Patrice
Peytavin, Gilles
André-Garnier, Elisabeth
Bettinger, Dominique
Ferré, Virginie
Hoen, Bruno
Raffi, François
description Nucleoside reverse transcriptase inhibitor (NRTI) and protease inhibitor (PI)/ritonavir sparing regimens may be useful to some HIV-infected patients. Nevirapine (NVP) and raltegravir (RAL) are both potent antiretrovirals with good long-term safety profiles. We retrospectively identified from our electronic database all patients with HIV RNA6 months on an NVP-containing regimen and no prior exposure to integrase strand transfer inhibitors who were switched to RAL plus NVP. Data was collected for 36 months or until discontinuation of RAL plus NVP for any reason. A total of 39 patients (30 male) were included in this analysis. Median duration of prior antiretroviral therapy was 14 years (IQR 10-17) and median duration with plasma HIV-1 RNA
format article
fullrecord <record><control><sourceid>hal</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_01115499v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>oai_HAL_hal_01115499v1</sourcerecordid><originalsourceid>FETCH-hal_primary_oai_HAL_hal_01115499v13</originalsourceid><addsrcrecordid>eNqVjd1Kw0AQhfdCsfXnHeZWMJhtssVciigJSBEp3oYxnaYjm91ldi3kaXxVt-ALeHU4Hx_nnKmlrkxTrE1lFuoyxq-yXD00ZXmhFqta16Zam6X62dCRBQM7KgRtolEwAxj89MkOE3t3B-hg877tcu7grbsXiAGF3QhCI090MiJMyC6RQzdQFhMLJfGnbQvpQPliBnaQgbd-5AGtnSF-hyAUI-2g7T4KXbDb05ByDfmaXIrX6nyPNtLNX16p25fn7VNbHND2QXhCmXuP3LePr_2JlVprUzfNUVf_cX8BboNhkg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Nevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients</title><source>SAGE Open Access</source><creator>Reliquet, Véronique ; Chirouze, Catherine ; Allavena, Clotilde ; Muret, Patrice ; Peytavin, Gilles ; André-Garnier, Elisabeth ; Bettinger, Dominique ; Ferré, Virginie ; Hoen, Bruno ; Raffi, François</creator><creatorcontrib>Reliquet, Véronique ; Chirouze, Catherine ; Allavena, Clotilde ; Muret, Patrice ; Peytavin, Gilles ; André-Garnier, Elisabeth ; Bettinger, Dominique ; Ferré, Virginie ; Hoen, Bruno ; Raffi, François</creatorcontrib><description>Nucleoside reverse transcriptase inhibitor (NRTI) and protease inhibitor (PI)/ritonavir sparing regimens may be useful to some HIV-infected patients. Nevirapine (NVP) and raltegravir (RAL) are both potent antiretrovirals with good long-term safety profiles. We retrospectively identified from our electronic database all patients with HIV RNA&lt;50 copies/ml for &gt;6 months on an NVP-containing regimen and no prior exposure to integrase strand transfer inhibitors who were switched to RAL plus NVP. Data was collected for 36 months or until discontinuation of RAL plus NVP for any reason. A total of 39 patients (30 male) were included in this analysis. Median duration of prior antiretroviral therapy was 14 years (IQR 10-17) and median duration with plasma HIV-1 RNA&lt;50 copies/ml prior to switch was 50 months (IQR 22-96). Switched regimens included mainly a boosted PI (n=24) or tenofovir disoproxil fumarate/emtricitabine (n=12). After switching, the percentages of patients with HIV-1 RNA&lt;50 copies/ml were 87.2% (95% CI 76.7, 97.7) and 82.1% (95% CI 70.0, 94.1) at 6 and 12 months, respectively, in the intent-to-treat-exposed analysis, 97.1% (95% CI 91.6, 100) and 94.1% (95% CI 86.2, 100), respectively, in the per-protocol analysis. All patients with follow-up to month 24 (n=22) or month 36 (n=14) had HIV-1 RNA&lt;50 copies/ml. One virological failure was observed (related to archived non-nucleoside reverse transcriptase inhibitor resistance mutation). During follow-up, no patient experienced Grade 3 or 4 adverse events. Median values of serum creatinine and lipids significantly improved after switch. In patients with prolonged HIV-1 RNA&lt;50 copies/ml, switching to NVP-RAL combination maintained virological suppression throughout 36 months. This combination deserves further evaluation in patients unable to tolerate NRTI or PI/ritonavir agents.</description><identifier>ISSN: 1359-6535</identifier><identifier>PMID: 24145365</identifier><language>eng</language><publisher>International Medical Press</publisher><subject>Antiretroviral Therapy, Highly Active ; CD4 Lymphocyte Count ; Drug Combinations ; Drug Substitution ; Female ; Follow-Up Studies ; HIV Infections ; HIV-1 ; Humans ; Life Sciences ; Male ; Microbiology and Parasitology ; Middle Aged ; Nevirapine ; Protease Inhibitors ; Pyrrolidinones ; Retrospective Studies ; Reverse Transcriptase Inhibitors ; Risk Factors ; Treatment Outcome ; Viral Load</subject><ispartof>Antiviral therapy, 2013-11, Vol.19 (1), p.117-23</ispartof><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0003-1010-1270 ; 0000-0002-6150-2376 ; 0000-0003-3070-3017 ; 0000-0002-6150-2376 ; 0000-0003-1010-1270 ; 0000-0003-3070-3017</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885</link.rule.ids><backlink>$$Uhttps://hal.science/hal-01115499$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Reliquet, Véronique</creatorcontrib><creatorcontrib>Chirouze, Catherine</creatorcontrib><creatorcontrib>Allavena, Clotilde</creatorcontrib><creatorcontrib>Muret, Patrice</creatorcontrib><creatorcontrib>Peytavin, Gilles</creatorcontrib><creatorcontrib>André-Garnier, Elisabeth</creatorcontrib><creatorcontrib>Bettinger, Dominique</creatorcontrib><creatorcontrib>Ferré, Virginie</creatorcontrib><creatorcontrib>Hoen, Bruno</creatorcontrib><creatorcontrib>Raffi, François</creatorcontrib><title>Nevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients</title><title>Antiviral therapy</title><description>Nucleoside reverse transcriptase inhibitor (NRTI) and protease inhibitor (PI)/ritonavir sparing regimens may be useful to some HIV-infected patients. Nevirapine (NVP) and raltegravir (RAL) are both potent antiretrovirals with good long-term safety profiles. We retrospectively identified from our electronic database all patients with HIV RNA&lt;50 copies/ml for &gt;6 months on an NVP-containing regimen and no prior exposure to integrase strand transfer inhibitors who were switched to RAL plus NVP. Data was collected for 36 months or until discontinuation of RAL plus NVP for any reason. A total of 39 patients (30 male) were included in this analysis. Median duration of prior antiretroviral therapy was 14 years (IQR 10-17) and median duration with plasma HIV-1 RNA&lt;50 copies/ml prior to switch was 50 months (IQR 22-96). Switched regimens included mainly a boosted PI (n=24) or tenofovir disoproxil fumarate/emtricitabine (n=12). After switching, the percentages of patients with HIV-1 RNA&lt;50 copies/ml were 87.2% (95% CI 76.7, 97.7) and 82.1% (95% CI 70.0, 94.1) at 6 and 12 months, respectively, in the intent-to-treat-exposed analysis, 97.1% (95% CI 91.6, 100) and 94.1% (95% CI 86.2, 100), respectively, in the per-protocol analysis. All patients with follow-up to month 24 (n=22) or month 36 (n=14) had HIV-1 RNA&lt;50 copies/ml. One virological failure was observed (related to archived non-nucleoside reverse transcriptase inhibitor resistance mutation). During follow-up, no patient experienced Grade 3 or 4 adverse events. Median values of serum creatinine and lipids significantly improved after switch. In patients with prolonged HIV-1 RNA&lt;50 copies/ml, switching to NVP-RAL combination maintained virological suppression throughout 36 months. This combination deserves further evaluation in patients unable to tolerate NRTI or PI/ritonavir agents.</description><subject>Antiretroviral Therapy, Highly Active</subject><subject>CD4 Lymphocyte Count</subject><subject>Drug Combinations</subject><subject>Drug Substitution</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>HIV Infections</subject><subject>HIV-1</subject><subject>Humans</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Microbiology and Parasitology</subject><subject>Middle Aged</subject><subject>Nevirapine</subject><subject>Protease Inhibitors</subject><subject>Pyrrolidinones</subject><subject>Retrospective Studies</subject><subject>Reverse Transcriptase Inhibitors</subject><subject>Risk Factors</subject><subject>Treatment Outcome</subject><subject>Viral Load</subject><issn>1359-6535</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNqVjd1Kw0AQhfdCsfXnHeZWMJhtssVciigJSBEp3oYxnaYjm91ldi3kaXxVt-ALeHU4Hx_nnKmlrkxTrE1lFuoyxq-yXD00ZXmhFqta16Zam6X62dCRBQM7KgRtolEwAxj89MkOE3t3B-hg877tcu7grbsXiAGF3QhCI090MiJMyC6RQzdQFhMLJfGnbQvpQPliBnaQgbd-5AGtnSF-hyAUI-2g7T4KXbDb05ByDfmaXIrX6nyPNtLNX16p25fn7VNbHND2QXhCmXuP3LePr_2JlVprUzfNUVf_cX8BboNhkg</recordid><startdate>20131130</startdate><enddate>20131130</enddate><creator>Reliquet, Véronique</creator><creator>Chirouze, Catherine</creator><creator>Allavena, Clotilde</creator><creator>Muret, Patrice</creator><creator>Peytavin, Gilles</creator><creator>André-Garnier, Elisabeth</creator><creator>Bettinger, Dominique</creator><creator>Ferré, Virginie</creator><creator>Hoen, Bruno</creator><creator>Raffi, François</creator><general>International Medical Press</general><scope>1XC</scope><orcidid>https://orcid.org/0000-0003-1010-1270</orcidid><orcidid>https://orcid.org/0000-0002-6150-2376</orcidid><orcidid>https://orcid.org/0000-0003-3070-3017</orcidid><orcidid>https://orcid.org/0000-0002-6150-2376</orcidid><orcidid>https://orcid.org/0000-0003-1010-1270</orcidid><orcidid>https://orcid.org/0000-0003-3070-3017</orcidid></search><sort><creationdate>20131130</creationdate><title>Nevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients</title><author>Reliquet, Véronique ; Chirouze, Catherine ; Allavena, Clotilde ; Muret, Patrice ; Peytavin, Gilles ; André-Garnier, Elisabeth ; Bettinger, Dominique ; Ferré, Virginie ; Hoen, Bruno ; Raffi, François</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-hal_primary_oai_HAL_hal_01115499v13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Antiretroviral Therapy, Highly Active</topic><topic>CD4 Lymphocyte Count</topic><topic>Drug Combinations</topic><topic>Drug Substitution</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>HIV Infections</topic><topic>HIV-1</topic><topic>Humans</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Microbiology and Parasitology</topic><topic>Middle Aged</topic><topic>Nevirapine</topic><topic>Protease Inhibitors</topic><topic>Pyrrolidinones</topic><topic>Retrospective Studies</topic><topic>Reverse Transcriptase Inhibitors</topic><topic>Risk Factors</topic><topic>Treatment Outcome</topic><topic>Viral Load</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Reliquet, Véronique</creatorcontrib><creatorcontrib>Chirouze, Catherine</creatorcontrib><creatorcontrib>Allavena, Clotilde</creatorcontrib><creatorcontrib>Muret, Patrice</creatorcontrib><creatorcontrib>Peytavin, Gilles</creatorcontrib><creatorcontrib>André-Garnier, Elisabeth</creatorcontrib><creatorcontrib>Bettinger, Dominique</creatorcontrib><creatorcontrib>Ferré, Virginie</creatorcontrib><creatorcontrib>Hoen, Bruno</creatorcontrib><creatorcontrib>Raffi, François</creatorcontrib><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Antiviral therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Reliquet, Véronique</au><au>Chirouze, Catherine</au><au>Allavena, Clotilde</au><au>Muret, Patrice</au><au>Peytavin, Gilles</au><au>André-Garnier, Elisabeth</au><au>Bettinger, Dominique</au><au>Ferré, Virginie</au><au>Hoen, Bruno</au><au>Raffi, François</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients</atitle><jtitle>Antiviral therapy</jtitle><date>2013-11-30</date><risdate>2013</risdate><volume>19</volume><issue>1</issue><spage>117</spage><epage>23</epage><pages>117-23</pages><issn>1359-6535</issn><abstract>Nucleoside reverse transcriptase inhibitor (NRTI) and protease inhibitor (PI)/ritonavir sparing regimens may be useful to some HIV-infected patients. Nevirapine (NVP) and raltegravir (RAL) are both potent antiretrovirals with good long-term safety profiles. We retrospectively identified from our electronic database all patients with HIV RNA&lt;50 copies/ml for &gt;6 months on an NVP-containing regimen and no prior exposure to integrase strand transfer inhibitors who were switched to RAL plus NVP. Data was collected for 36 months or until discontinuation of RAL plus NVP for any reason. A total of 39 patients (30 male) were included in this analysis. Median duration of prior antiretroviral therapy was 14 years (IQR 10-17) and median duration with plasma HIV-1 RNA&lt;50 copies/ml prior to switch was 50 months (IQR 22-96). Switched regimens included mainly a boosted PI (n=24) or tenofovir disoproxil fumarate/emtricitabine (n=12). After switching, the percentages of patients with HIV-1 RNA&lt;50 copies/ml were 87.2% (95% CI 76.7, 97.7) and 82.1% (95% CI 70.0, 94.1) at 6 and 12 months, respectively, in the intent-to-treat-exposed analysis, 97.1% (95% CI 91.6, 100) and 94.1% (95% CI 86.2, 100), respectively, in the per-protocol analysis. All patients with follow-up to month 24 (n=22) or month 36 (n=14) had HIV-1 RNA&lt;50 copies/ml. One virological failure was observed (related to archived non-nucleoside reverse transcriptase inhibitor resistance mutation). During follow-up, no patient experienced Grade 3 or 4 adverse events. Median values of serum creatinine and lipids significantly improved after switch. In patients with prolonged HIV-1 RNA&lt;50 copies/ml, switching to NVP-RAL combination maintained virological suppression throughout 36 months. This combination deserves further evaluation in patients unable to tolerate NRTI or PI/ritonavir agents.</abstract><pub>International Medical Press</pub><pmid>24145365</pmid><orcidid>https://orcid.org/0000-0003-1010-1270</orcidid><orcidid>https://orcid.org/0000-0002-6150-2376</orcidid><orcidid>https://orcid.org/0000-0003-3070-3017</orcidid><orcidid>https://orcid.org/0000-0002-6150-2376</orcidid><orcidid>https://orcid.org/0000-0003-1010-1270</orcidid><orcidid>https://orcid.org/0000-0003-3070-3017</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1359-6535
ispartof Antiviral therapy, 2013-11, Vol.19 (1), p.117-23
issn 1359-6535
language eng
recordid cdi_hal_primary_oai_HAL_hal_01115499v1
source SAGE Open Access
subjects Antiretroviral Therapy, Highly Active
CD4 Lymphocyte Count
Drug Combinations
Drug Substitution
Female
Follow-Up Studies
HIV Infections
HIV-1
Humans
Life Sciences
Male
Microbiology and Parasitology
Middle Aged
Nevirapine
Protease Inhibitors
Pyrrolidinones
Retrospective Studies
Reverse Transcriptase Inhibitors
Risk Factors
Treatment Outcome
Viral Load
title Nevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T18%3A28%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-hal&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nevirapine-raltegravir%20combination,%20an%20NRTI%20and%20PI/r%20sparing%20regimen,%20as%20maintenance%20antiretroviral%20therapy%20in%20virologically%20suppressed%20HIV-1-infected%20patients&rft.jtitle=Antiviral%20therapy&rft.au=Reliquet,%20V%C3%A9ronique&rft.date=2013-11-30&rft.volume=19&rft.issue=1&rft.spage=117&rft.epage=23&rft.pages=117-23&rft.issn=1359-6535&rft_id=info:doi/&rft_dat=%3Chal%3Eoai_HAL_hal_01115499v1%3C/hal%3E%3Cgrp_id%3Ecdi_FETCH-hal_primary_oai_HAL_hal_01115499v13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/24145365&rfr_iscdi=true